Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Retained Earnings (2016 - 2025)

Acro Biomedical has reported Retained Earnings over the past 10 years, most recently at -$32.8 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$32.8 million for Q4 2025, changed 0.31% from a year ago — trailing twelve months through Dec 2025 was -$32.8 million (changed 0.31% YoY), and the annual figure for FY2025 was -$32.8 million, changed 0.31%.
  • Retained Earnings for Q4 2025 was -$32.8 million at Acro Biomedical, roughly flat from -$32.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for ACBM hit a ceiling of -$298148.0 in Q1 2021 and a floor of -$32.8 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$31.8 million (2023), compared with a mean of -$23.5 million.
  • Biggest five-year swings in Retained Earnings: tumbled 3879.66% in 2022 and later decreased 0.13% in 2025.
  • Acro Biomedical's Retained Earnings stood at -$7.9 million in 2021, then crashed by 199.98% to -$23.8 million in 2022, then crashed by 36.99% to -$32.6 million in 2023, then fell by 0.13% to -$32.7 million in 2024, then fell by 0.31% to -$32.8 million in 2025.
  • The last three reported values for Retained Earnings were -$32.8 million (Q4 2025), -$32.8 million (Q3 2025), and -$32.7 million (Q2 2025) per Business Quant data.